Evranos B, Polat S B, Baser H, Ozdemir D, Kilicarslan A, Yalcin A, Ersoy R, Cakir B
Department of Endocrinology and Metabolism, Ataturk Education and Research Hospital, Yildirim Beyazit University, Ankara, Turkey.
Department of Pathology, Ataturk Education and Research Hospital, Yildirim Beyazit University, Ankara, Turkey.
Cytopathology. 2017 Aug;28(4):259-267. doi: 10.1111/cyt.12384. Epub 2016 Sep 25.
A fine needle aspiration biopsy (FNAB) is the most valuable diagnostic procedure for pre-operative discrimination of benign and malignant nodules. The Bethesda System for Reporting Thyroid Cytopathology provides standardised reporting and cytomorphological criteria in aspiration smears. The aim of the present study was to determine malignancy rates in nodules with different cytology results and evaluate the diagnostic value of Bethesda for variants of papillary thyroid carcinoma (PTC).
A retrospective analysis of 2534 cases with 5784 thyroid nodules, who underwent FNAB followed by surgery, were included in this study. FNAB was performed with ultrasonography guidance. Cytological diagnoses were classified as: non-diagnostic (ND), benign, atypia of undetermined significance/follicular lesions of undetermined significance (AUS/FLUS), follicular neoplasm/suspicious for follicular neoplasm (FN/SFN), suspicious for malignancy (SUS) and malignant. Histopathological diagnoses were classified into four groups: benign, PTC, follicular thyroid cancer and other types of thyroid cancer (including medullary thyroid cancer, undifferentiated thyroid cancer and thyroid tumours of uncertain malignant potential). Cases with PTC were further divided into four categories: conventional variant, follicular variant, aggressive variants (tall cell, diffuse sclerosing and columnar variant) and other variants (oncocytic, solid/trabecular and warthin-like variants). FNAB results were compared with histopathological results.
Malignancy rates were 6.3%, 3.2%, 20.7%, 33.3%, 74.2% and 95.6% in the nodules with ND, benign, AUS/FLUS, FN/SFN, SUS and malignant cytology results, respectively. Pre-operative cytology was malignant or SUS in 56.6% of conventional, 24.3% of follicular, 92% of aggressive and 41.7% of other variants of histopathologically confirmed PTC. The difference between the groups was significant (P < 0.001).
The Bethesda classification is a reliable indicator of malignancy in nodules with different cytology results and seems to be very effective in predicting the malignancy for the nodules diagnosed with aggressive variant PTC on the final histological examination.
细针穿刺活检(FNAB)是术前鉴别甲状腺结节良恶性最有价值的诊断方法。甲状腺细胞病理学报告的贝塞斯达系统为细针穿刺涂片提供了标准化报告和细胞形态学标准。本研究的目的是确定不同细胞学结果的甲状腺结节的恶性率,并评估贝塞斯达系统对甲状腺乳头状癌(PTC)变异型的诊断价值。
本研究纳入了2534例共5784个甲状腺结节的病例,这些病例均接受了FNAB检查并随后接受了手术。FNAB在超声引导下进行。细胞学诊断分为:无法诊断(ND)、良性、意义不明确的非典型病变/意义不明确的滤泡性病变(AUS/FLUS)、滤泡性肿瘤/可疑滤泡性肿瘤(FN/SFN)、可疑恶性(SUS)和恶性。组织病理学诊断分为四组:良性、PTC、滤泡性甲状腺癌和其他类型的甲状腺癌(包括髓样甲状腺癌、未分化甲状腺癌和恶性潜能不确定的甲状腺肿瘤)。PTC病例进一步分为四类:经典型、滤泡型、侵袭性变异型(高细胞型、弥漫硬化型和柱状细胞型)和其他变异型(嗜酸细胞型、实性/小梁状和沃辛样变异型)。将FNAB结果与组织病理学结果进行比较。
细胞学结果为ND、良性、AUS/FLUS、FN/SFN、SUS和恶性的甲状腺结节的恶性率分别为6.3%、3.2%、20.7%、33.3%、74.2%和95.6%。在组织病理学确诊为PTC的病例中,经典型的术前细胞学诊断为恶性或SUS的比例为56.6%,滤泡型为24.3%,侵袭性变异型为92%,其他变异型为41.7%。各组之间差异有统计学意义(P<0.001)。
贝塞斯达分类是不同细胞学结果的甲状腺结节恶性程度的可靠指标,对于最终组织学检查诊断为侵袭性变异型PTC的甲状腺结节,该分类在预测其恶性程度方面似乎非常有效。